Utilizing biomarkers in atrial fibrillation: the pros and cons

Cardiovasc Res. 2022 Jul 20;118(9):2035-2036. doi: 10.1093/cvr/cvab283.

Authors

Wern Yew Ding¹, Garry McDowell^{1

2}, Gregory Y H Lip^{1

3}

Affiliations

¹ Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.
² School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.
³ Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

PMID: 34431986
DOI: 10.1093/cvr/cvab283

No abstract available

Publication types

Editorial
Comment

MeSH terms

Anticoagulants
Atrial Fibrillation* / diagnosis
Biomarkers
Cardiovascular System*
Heart
Humans

Substances

Anticoagulants
Biomarkers